The GLP-1 market is on track to hit 190B by 2035 - priced almost entirely as weight loss
When you have a drug that drops depression risk 44%, anxiety 38%, and substance use 47% as a side effect
you're not looking at a weight loss category anymore
Crémieux@cremieuxrecueil
We now have causal evidence on semaglutide and mental health! By comparing people when they're off versus when they're on the drug, we can see how their mental state differs. When they're on, they're less likely to get depressed, anxious, to abuse other drugs, or to miss work.
English